Researchers Uncover Molecular Basis of Infection of Tick-Transmitted Disease
Source Newsroom: Virginia Commonwealth University
Newswise — RICHMOND, Va. (Oct. 12, 2012) – Virginia Commonwealth University School of Medicine researchers have identified the “keys” and “doors” of a bacterium responsible for a series of tick-transmitted diseases. These findings may point researchers toward the development of a single vaccine that protects against members of an entire family of bacteria that cause disease in humans, domestic animals and livestock.
Survival for many bacteria is dependent on their ability to invade human or animal cells. And it needs to be done in a very precise fashion. Bacteria use a specific set of “keys” on their surfaces to unlock specific “doors,” or entryways into their host cells.
By understanding how these bacteria invade cells, researchers are able to identify potential targets to block the spread of infection, and from there, develop safe and effective vaccines.
In the study, now published online and appearing in the November (Volume 80, Issue 11) issue of the journal Infection and Immunity, a journal of the American Society for Microbiology, researchers reported that a protein called OmpA on the surface of Anaplasma phagocytophilum is important for invading host cells. Anaplasma phagocytophilum is an Anaplasmataceae bacterium that infects humans to cause granulocytic anaplasmosis. It is the second most common tick-transmitted disease after Lyme disease in the United States, and it also is found in Europe and Asia.
The team also identified the particular sugar residue on the surfaces of host cells to which OmpA binds.
“In other words, we identified both a key and door that together promote Anaplasma phagocytophilum infection,” said lead investigator Jason A. Carlyon, Ph.D., associate professor and a George and Lavinia Blick Scholar in the Department of Microbiology and Immunology in the VCU School of Medicine.
“These findings are important because our data also establish a direction for development of a single vaccine that protects against members of an entire family of bacteria that cause disease in humans, domestic animals and livestock,” he said.
According to Carlyon, the region of OmpA that mediates infection is shared among other Anaplasmataceae bacteria.
Experts have seen a steady rise in the incidence of human infections caused by tick-transmitted bacterial pathogens in the past several years. Many tick-transmitted bacterial pathogens are considered “emerging pathogens” because it was only recently discovered that they infect humans. Moreover, evidence suggests that many of these infections go unrecognized, signifying that the prevalence of human diseases caused by Anaplasmataceae pathogens is even higher, said Carlyon. Livestock infections carry a significant economic burden, costing the U.S. cattle industry $100 million per year, he added.
Researchers in Carlyon’s lab are presently refining their understanding of how OmpA promotes infection and testing its efficacy in protecting against infection by A. phagocytophilum and other Anaplasmataceae members.
The findings of the VCU-led study were also highlighted in a commentary that appeared in the same issue of the journal, authored by two experts in the field, including Guy H. Palmer, DVM, Ph.D., director, Creighton chair and Regents professor in the Paul G. Allen School for Global Animal Health at the Washington State University College of Veterinary Medicine, and Susan M. Noh, Ph.D., also with Washington State University College of Veterinary Medicine.
For this work, VCU has filed a patent. At this time, U.S. and foreign rights are available, and the team is seeking commercial partners to further develop this technology.
Carlyon collaborated with VCU School of Medicine researchers Nore Ojogun, Ph.D.; Amandeep Kahlon, Ph.D.; Matthew J. Troese, Ph.D.; and Rachael J. Thomas, Ph.D., all former postdoctoral fellows in the VCU Department of Microbiology and Immunology and Carlyon’s lab; Stephanie A. Ragland, former laboratory technician in the VCU Department of Microbiology and Immunology; Lauren VieBrock, graduate student in the VCU Department of Microbiology and Immunology, both also in Carlyon’s lab; Juliana E. Masttronunzio, Ph.D., postdoctoral fellow in the Yale University School of Medicine, and Erol Fikrig, M.D., Waldemar Von Zedtwitz professor of medicine and epidemiology and microbial pathogenesis in the Yale University School of Medicine, and investigator with Howard Hughes Medical Institute, and section chief of infectious diseases; and Naomi J. Walker, technician with the University of California School of Veterinary Medicine, and Dori L. Borjesson, Ph.D., professor from the University of California School of Veterinary Medicine.
This study was supported by a grant from the National Institutes of Health grants R01 AI072683, R01AI072683-04S1, and R21 AI090170 (to Carlyon) and R01 AI141440 (to Fikrig). The VCU Flow Cytometry and Imaging Shared Resource Facility is supported, in part, by funding from NIH-NCI Cancer Center Support Grant 5 P30 CA016059.
Read the abstract here: http://iai.asm.org/content/80/11/3748.abstract?etoc
EDITOR’S NOTE: A copy of the study is available for reporters by contacting the journal’s communications office at 202.737.3600 or email@example.com.
About VCU and the VCU Medical Center: Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located in downtown Richmond, VCU enrolls more than 31,000 students in 222 degree and certificate programs in the arts, sciences and humanities. Sixty-six of the programs are unique in Virginia, many of them crossing the disciplines of VCU’s 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation’s leading academic medical centers. For more, see www.vcu.edu.